FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 11
Grant agreement number
807010

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
1 168 750
EFPIA in kind
615 629
Other
337 500
Total Cost
2 121 879

Summary

One of the most significant outputs of IMI’s WEB-RADR project was a mobile application (app) which allows patients and healthcare professionals to report adverse drug reactions (ADRs, or side effects) directly to the relevant authorities. The WEB-RADR 2 project aims to take the app to the next level by making its functionalities available through application programming interfaces (APIs). This will allow third party organisations to embed the WEB-RADR platform’s functionality into their own systems, apps and websites. To achieve this, the team will collaborate with main organisations involved in pharmacovigilance to map the terminologies used. They will also work closely with the WEB RADR project’s networks of regulatory authorities, health charities and system providers to ensure the tools developed are what end users need.

Achievements & News

WEB-RADR issues recommendations on use of social media for pharmacovigilance
September 2019

Generally speaking, social media is currently not suitable for detecting new safety issues in marketed medicines, according to a new paper published by the WEB-RADR project in the journal Drug Safety. Nevertheless, it may be beneficial in certain specific circumstances, and advances in technology may make it more useful in the future. Once a medicine is on the market, drug companies and medicines regulators monitor its safety in the general population in the long term. To do this, they rely on patients and healthcare professionals to report suspected problems (known as adverse drug reactions or ADRs). However, many suspected ADRs go unreported. WEB-RADR set out to determine if social media could be used to identify ADRs. To do this, the team studied some 4.2 million tweets and Facebook posts as well as over 42 000 posts from over 400 online patient fora. Overall, they conclude that social media, such as Facebook and Twitter, are not recommended for detecting potential safety issues. However, social media may prove useful in certain niche areas, such as exposure to medicines during pregnancy and the abuse (or misuse) of medicines. Furthermore, advances in technology could mean that social media could be used as a source of information on ADRs in the future.

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Csl Behring GMBH, Marburg, Germany
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain
  • International Health Terminology Standards Development Organisation, London, United Kingdom
  • Laegemiddelstyrelsen, Kobenhavn S, Denmark
  • Medicines And Healthcare Products Regulatory Agency, London, United Kingdom
  • Stichting Lareb, 's Hertogenbosch, Netherlands
  • Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
  • The International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use, Geneve, Switzerland

CONTACT

Project coordinator
Phil TREGUNNO
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
Phil.Tregunno[at]mhra.gov.uk